230 related articles for article (PubMed ID: 33231796)
21. Immunohistochemical analysis of nm23 protein expression in malignant bone tumors.
Oda Y; Walter H; Radig K; Röse I; Neumann W; Roessner A
J Cancer Res Clin Oncol; 1995; 121(11):667-73. PubMed ID: 7593131
[TBL] [Abstract][Full Text] [Related]
22. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
[TBL] [Abstract][Full Text] [Related]
23. Homogenous and Heterogenous Prognostic Factors for Patients with Bone Sarcoma.
Xu G; Wu H; Xu Y; Zhang Y; Lin F; Baklaushev VP; Chekhonin VP; Peltzer K; Wang X; Mao M; Wang G; Cui P; Zhang C
Orthop Surg; 2021 Feb; 13(1):134-144. PubMed ID: 33305494
[TBL] [Abstract][Full Text] [Related]
24. PD-1 and PD-L1 expression in bone and soft tissue sarcomas.
Torabi A; Amaya CN; Wians FH; Bryan BA
Pathology; 2017 Aug; 49(5):506-513. PubMed ID: 28688724
[TBL] [Abstract][Full Text] [Related]
25. Soluble forms of PD-1/PD-L immune checkpoint receptor and ligand in blood serum of breast cancer patients: association with clinical pathologic factors and molecular type of the tumor.
Gershtein ES; Korotkova EA; Vorotnikov IK; Sokolov NY; Ermilova VD; Mochalova AS; Kushlinskii NE
Klin Lab Diagn; 2022 Feb; 67(2):76-80. PubMed ID: 35192751
[TBL] [Abstract][Full Text] [Related]
26. Bone sarcoma incidence in the Netherlands.
Goedhart LM; Ho VKY; Dijkstra PDS; Schreuder HWB; Schaap GR; Ploegmakers JJW; van der Geest ICM; van de Sande MAJ; Bramer JA; Suurmeijer AJH; Jutte PC
Cancer Epidemiol; 2019 Jun; 60():31-38. PubMed ID: 30903831
[TBL] [Abstract][Full Text] [Related]
27. Round cell tumors of bone: an update on recent molecular genetic advances.
Wei S; Siegal GP
Adv Anat Pathol; 2014 Sep; 21(5):359-72. PubMed ID: 25105937
[TBL] [Abstract][Full Text] [Related]
28. Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival.
Tilan JU; Krailo M; Barkauskas DA; Galli S; Mtaweh H; Long J; Wang H; Hawkins K; Lu C; Jeha D; Izycka-Swieszewska E; Lawlor ER; Toretsky JA; Kitlinska JB
Cancer; 2015 Mar; 121(5):697-707. PubMed ID: 25387699
[TBL] [Abstract][Full Text] [Related]
29. Twenty-year outcome of prevalence, incidence, mortality and survival rate in patients with malignant bone tumors.
Xu Y; Shi F; Zhang Y; Yin M; Han X; Feng J; Wang G
Int J Cancer; 2024 Jan; 154(2):226-240. PubMed ID: 37596989
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT).
Machado I; López-Guerrero JA; Scotlandi K; Picci P; Llombart-Bosch A
Virchows Arch; 2018 May; 472(5):815-824. PubMed ID: 29445891
[TBL] [Abstract][Full Text] [Related]
31. Clinical and prognostic significance of the soluble form of the VISTA immunity control point in patients with primary bone tumors.
Kushlinskii NE; Kovaleva OV; Kuzmin YB; Korotkova EA; Gershtein ES; Boulytcheva IV; Kozlova EV; Kudlay DA; Podlesnaya PA; Gratchev AN; Kuznetsov IN; Sushentsov EA
Klin Lab Diagn; 2021 Sep; 66(9):533-538. PubMed ID: 34543531
[TBL] [Abstract][Full Text] [Related]
32. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
[TBL] [Abstract][Full Text] [Related]
33. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.
Majzner RG; Simon JS; Grosso JF; Martinez D; Pawel BR; Santi M; Merchant MS; Geoerger B; Hezam I; Marty V; Vielh P; Daugaard M; Sorensen PH; Mackall CL; Maris JM
Cancer; 2017 Oct; 123(19):3807-3815. PubMed ID: 28608950
[TBL] [Abstract][Full Text] [Related]
34. Small round cell tumors of bone.
Hameed M
Arch Pathol Lab Med; 2007 Feb; 131(2):192-204. PubMed ID: 17284103
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of factors affecting survival rate in primary bone sarcomas with extremity and pelvis involvement.
Sofulu Ö; Erol B
Acta Orthop Traumatol Turc; 2020 May; 54(3):234-244. PubMed ID: 32544060
[TBL] [Abstract][Full Text] [Related]
36. Epidemiologic and survival trends in adult primary bone tumors of the spine.
Kerr DL; Dial BL; Lazarides AL; Catanzano AA; Lane WO; Blazer DG; Brigman BE; Mendoza-Lattes S; Eward WC; Erickson ME
Spine J; 2019 Dec; 19(12):1941-1949. PubMed ID: 31306757
[TBL] [Abstract][Full Text] [Related]
37. Clear cell tumors of bone.
Swanson PE
Semin Diagn Pathol; 1997 Nov; 14(4):281-91. PubMed ID: 9383827
[TBL] [Abstract][Full Text] [Related]
38. Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer.
Zhang J; Zhang H; Luo Y
Med Sci Monit; 2019 Feb; 25():1275-1282. PubMed ID: 30771277
[TBL] [Abstract][Full Text] [Related]
39. Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment.
Oh SY; Kim S; Keam B; Kim TM; Kim DW; Heo DS
Sci Rep; 2021 Oct; 11(1):19712. PubMed ID: 34611279
[TBL] [Abstract][Full Text] [Related]
40. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
